Neurelis
PrivateLast Round
Series D
Aug 26, 2022
Total Funding Raised
$391.4M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Neurelis is a neuroscience company that develops and commercializes therapeutics for the treatment of epilepsy and other central nervous system disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neurelis Comparables
Compare Neurelis with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Aquestive Therapeutics Inc | 83% | |
| UCB | 77% | |
| Bausch Health Companies | 74% | |
Neurelis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Aug 26, 2022 | ||||
| Debt | Aug 11, 2021 | ||||
| Series D | Mar 10, 2021 | ||||
| Series D | Oct 21, 2020 | ||||
| Series C | Nov 8, 2018 | ||||
Series B | Jan 5, 2017 |
Secondary Market Activity
Bids, offers, and trades by month
| Operation | Date | Price | Size | Share Class | Structure |
|---|---|---|---|---|---|
BID |
Neurelis Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CMS Medical Venture Investment (HK) Limited | Series C |
| LYZZ Capital | Series C, Series B, Series A, Series D |
| Cormorant Asset Management | Series D |
| OrbiMed | Debt |
| HBM Healthcare Investments | Series D, Series C, Series B |
| Philos & Partners Ltd. | Series D |
| Cormorant Asset Management | Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 21, 2026
Monthly visitors increased 38% MoM.
- Apr 23, 2026
Attending Epilepsy Awareness Day at Walt Disney World.
Neurelis Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Neurelis's valuation, stock price, and market status.